Monday, January 27, 2020 9:49:21 AM
from Alexion website:
Immune Pharma - anti-eotaxin-1 antibody
Phase: Preclinical
In November 2019, Alexion acquired an anti-eotaxin-1 antibody from Immune Pharma for potential development in inflammatory diseases.
Immune Pharma - anti-eotaxin-1 antibody
Phase: Preclinical
In November 2019, Alexion acquired an anti-eotaxin-1 antibody from Immune Pharma for potential development in inflammatory diseases.
Recent MSLE News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/20/2026 12:00:17 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/15/2026 07:04:57 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/15/2026 11:00:07 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/12/2026 08:23:56 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/09/2026 11:00:08 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/27/2026 12:36:06 PM
- Form 40-F - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)] • Edgar (US Regulatory) • 03/27/2026 12:24:22 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/27/2026 11:00:06 AM
- Satellos Reports 2025 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 03/27/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/10/2026 11:00:10 AM
- Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference • GlobeNewswire Inc. • 03/10/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/24/2026 12:15:29 PM
- Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference • Business Wire • 02/24/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/19/2026 04:04:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/18/2026 07:02:58 PM
- Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy • Business Wire • 02/18/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/17/2026 08:22:46 PM
- Satellos to Participate in Upcoming Investor Conferences • Business Wire • 02/17/2026 12:00:00 PM
- Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 • Business Wire • 02/10/2026 12:00:00 PM
- Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares • Business Wire • 02/09/2026 10:00:00 PM
- Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States • Business Wire • 02/06/2026 01:30:00 PM
